Cooley, Latham Handle $686M AMAG-Allos Merger
Drug developers AMAG Pharmaceuticals Inc. and Allos Therapeutics Inc. announced Wednesday an all-stock merger valued at about $686 million that is expected to strengthen their product lines and streamline their costs....To view the full article, register now.
Already a subscriber? Click here to view full article